Highly Commended
CLEAR HORIZONS: A New Era of Psoriasis Care
Summary of work
Despite recent advances in the understanding of psoriasis and rapid expansion in treatment options available, most patients with moderate-to-severe psoriasis still receive delayed, inadequate or suboptimal treatment. The introduction of a new class of therapies, IL-23 inhibitors, has the potential to provide long-term efficacy beyond that currently achieved in clinical practice. CLEAR HORIZONS was designed to help physicians to understand the potential of this new treatment class and to introduce SKYRIZI, a new IL-23 inhibitor.CLEAR HORIZONS needed to establish an IL-23/SKYRIZI expert community where trial experience was limited, connect and share expertise across the globe and then drive change to clinical practice at a local level. The CLEAR HORIZONS programme focused on establishing and mobilising “Leaders of Change”; a connected and empowered group of global and local innovators who would inspire change in others. An immersive delegate journey of local and global touchpoints led to an experiential event that would ensure “Leaders of Change” had the knowledge, skills, resources and commitment to drive change and create momentum in their countries via an omnichannel implementation strategy. To date, 271 “Leaders of Change” have already inspired ~3,500 dermatologists across 30 countries, contributing to the launch of SKYRIZI exceeding all expectations.
Judges’ comments
The judges thought the strategy and tactical planning for CLEAR HORIZONS were outstanding. The process they went through stood out, resulting in a very effective larger scale cascade of information and education to a broad audience.
